Skip to content
Company Analysis

IRIDEX Corporation IRIX

A comprehensive view of key metrics, scores, and financial health for IRIDEX Corporation

Overview of IRIDEX Corporation

IRIX NCM
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Micro Cap
IRIDEX Corporation (IRIX), is a Micro Cap company, in the Medical Devices industry, last closed at $0.74, about 448.6% undervalued vs fair value, -26.7% 1Y return, ranked 798/1145 in sector.
Metrics Rev Growth 8.2% ROE -126.4% Gross Margin 36.5%
USD 0.74
-1.33%
(Delayed)
• Vol 90d: 69.2%
52-Week Range
Market Cap
$13.00M
Enterprise Value
$18.11M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Weak
Completeness: 88%
Confidence: 88%
Updated: Oct 24
Top Beats

Quick Facts

Website https://www.iridex.com
HQ Mountain View, CA
Employees 93
Fiscal year Dec 31

Next Events

Earnings Nov 17

Fair Value Snapshot

Bear Base Bull
$4
$4
$5
Current: $0.74 +449% vs base

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$52.7M
8.2%%
Gross Profit
$19.2M
-1.4%%
Operating Income (GAAP)
-$2.6M
69%%
EBITDA
-$1.0M
85.1%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
36.5%
Fair

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating IRIDEX Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
45
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Strong Operating Margin vs Peers Operating margin level is strong vs peers (score 0.71). SG&A discipline is converting gross margin into operating profit efficiently.
  • Expanding Operating Margin Operating margin trend is positive (score 0.60). Margin expansion confirms commercial leverage is building.

Key risks

  • Below-Peer Gross Margins Gross margin quality lags peers (score 0.21). May indicate commodity-like product mix or distributor margin drag.
  • Weak Capital Return Profile Capital return quality is below peers (score 0.27). Low ROIC raises questions about M&A discipline and pipeline ROI.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
37
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 83% Coverage
Trade-Off Triangle Visualization A ternary plot showing IRIX's balance between Growth (37.8%), Profitability (31.8%), and Safety (30.4%). Growth 38% Safety 30% Profitability 32%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

49th percentile vs peers
49
Key Signals
Rev Growth YoY 8.2% 54p EPS Growth YoY 51.7% 64p Revenue CAGR 3Y -2.6% 25p Asset Growth YoY 0.1% 47p
Strengths

No notable strengths identified for this axis.

Risks

No significant risks identified for this axis.

Profitability

41th percentile vs peers
41
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

39th percentile vs peers
39
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for IRIDEX Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$4.06
- - -
+448.6% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000